Total Payments
$39,798
2024 Payments
$2,328
Companies
39
Transactions
270
Medicare Patients
634
Medicare Billing
$473,506
Payment Breakdown by Category
Research$27,296 (68.6%)
Food & Beverage$7,112 (17.9%)
Travel$3,217 (8.1%)
Consulting$2,100 (5.3%)
Education$73.32 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $27,296 | 3 | 68.6% |
| Food and Beverage | $7,112 | 249 | 17.9% |
| Travel and Lodging | $3,217 | 11 | 8.1% |
| Consulting Fee | $2,100 | 1 | 5.3% |
| Education | $73.32 | 6 | 0.2% |
Payments by Type
Research
$27,296
3 transactions
General
$12,503
267 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $26,925 | 4 | $0 (2023) |
| Keryx Biopharmaceuticals, Inc. | $3,007 | 10 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $2,599 | 47 | $0 (2024) |
| AstraZeneca UK Limited | $1,372 | 8 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $764.75 | 25 | $0 (2024) |
| OPKO Pharmaceuticals, LLC | $518.31 | 26 | $0 (2024) |
| Otsuka Pharmaceutical Co., Ltd. | $425.79 | 1 | $0 (2018) |
| Vifor Pharma, Inc. | $382.97 | 21 | $0 (2023) |
| Amarin Pharma Inc. | $377.41 | 5 | $0 (2018) |
| Mallinckrodt Hospital Products Inc. | $318.80 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,328 | 36 | AstraZeneca Pharmaceuticals LP ($1,564) |
| 2023 | $1,932 | 64 | AstraZeneca Pharmaceuticals LP ($561.08) |
| 2022 | $1,097 | 50 | Bayer HealthCare Pharmaceuticals Inc. ($303.80) |
| 2021 | $704.53 | 32 | Bayer HealthCare Pharmaceuticals Inc. ($188.45) |
| 2020 | $494.86 | 21 | OPKO Pharmaceuticals, LLC ($110.32) |
| 2019 | $1,801 | 28 | AstraZeneca UK Limited ($1,247) |
| 2018 | $4,071 | 30 | Keryx Biopharmaceuticals, Inc. ($3,007) |
| 2017 | $27,370 | 9 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($26,870) |
All Payment Transactions
270 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Food and Beverage | In-kind items and services | $20.78 | General |
| Category: NEPHROLOGY | ||||||
| 12/05/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Education | In-kind items and services | $9.01 | General |
| Category: Nephrology | ||||||
| 11/09/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $25.83 | General |
| Category: IMMUNOLOGY | ||||||
| 11/01/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Food and Beverage | In-kind items and services | $24.56 | General |
| Category: Nephrology | ||||||
| 10/23/2024 | AKEBIA THERAPEUTICS INC | Auryxia (Drug), Vafseo | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Nephrology | ||||||
| 10/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $26.13 | General |
| Category: DIABETES | ||||||
| 10/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $26.92 | General |
| Category: Cardio-renal | ||||||
| 09/12/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $21.68 | General |
| Category: NEPHROLOGY | ||||||
| 09/06/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $13.37 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 08/30/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $24.31 | General |
| 08/28/2024 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Food and Beverage | In-kind items and services | $20.76 | General |
| Category: NEPHROLOGY | ||||||
| 08/09/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $35.20 | General |
| Category: IMMUNOLOGY | ||||||
| 06/28/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 06/25/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $25.25 | General |
| Category: IMMUNOLOGY | ||||||
| 06/21/2024 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Food and Beverage | In-kind items and services | $15.07 | General |
| Category: NEPHROLOGY | ||||||
| 06/13/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $25.48 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/11/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $602.95 | General |
| 06/11/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $367.08 | General |
| 06/11/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $205.18 | General |
| 06/11/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $134.09 | General |
| 06/11/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $51.32 | General |
| 06/11/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $49.67 | General |
| 06/11/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $39.73 | General |
| 06/11/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $34.77 | General |
| 06/11/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $34.77 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| OPEN-LABEL TRIAL TO EVALUATE THE LONG TERM SAFETY OF TITRATED IMMEDIATE-RELEASE TOLVAPTAN IN SUBJECTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $26,747 | 1 |
| PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE NDD-CKD PRO2TECT-CORRECTION | Otsuka Pharmaceutical Co., Ltd. | $425.79 | 1 |
| EFFICACY AND SAFETY OF TOLVAPTAN IN SUBJECTS WITH CHRONIC KIDNEY DISEASE BETWEEN LATE STAGE 2 TO EARLY STAGE 4 DUE TO AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $122.93 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 117 | 345 | $171,047 | $70,867 |
| 2022 | 5 | 161 | 556 | $291,646 | $120,591 |
| 2021 | 4 | 157 | 640 | $381,407 | $149,626 |
| 2020 | 4 | 199 | 697 | $393,078 | $132,423 |
Total Patients
634
Total Services
2,238
Medicare Billing
$473,506
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 33 | 200 | $145,200 | $56,771 | 39.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 65 | 126 | $21,420 | $11,822 | 55.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 19 | 19 | $4,427 | $2,275 | 51.4% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 40 | 344 | $249,744 | $98,706 | 39.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 82 | 170 | $28,900 | $16,262 | 56.3% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 11 | 13 | $7,865 | $3,097 | 39.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $3,262 | $1,524 | 46.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 14 | 15 | $1,875 | $1,002 | 53.4% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 56 | 443 | $321,618 | $127,681 | 39.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 75 | 168 | $28,560 | $16,241 | 56.9% |
| 90961 | Dialysis services (2-3 physician visits per month), patient 20 years of age and older | Office | 2021 | 15 | 18 | $28,435 | $3,981 | 14.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 11 | 11 | $2,794 | $1,723 | 61.7% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2020 | 76 | 500 | $363,000 | $116,120 | 32.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 72 | 145 | $22,125 | $11,722 | 53.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 19 | 19 | $4,133 | $2,315 | 56.0% |
| 99497 | Advance care planning by the physician or other qualified health care professional | Office | 2020 | 32 | 33 | $3,820 | $2,266 | 59.3% |
About Dr. Bhasker Mehta, MD
Dr. Bhasker Mehta, MD is a Specialist healthcare provider based in Arlington, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/11/2005. The National Provider Identifier (NPI) number assigned to this provider is 1790787612.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bhasker Mehta, MD has received a total of $39,798 in payments from pharmaceutical and medical device companies, with $2,328 received in 2024. These payments were reported across 270 transactions from 39 companies. The most common payment nature is "" ($27,296).
As a Medicare-enrolled provider, Mehta has provided services to 634 Medicare beneficiaries, totaling 2,238 services with total Medicare billing of $473,506. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Internal Medicine, Nephrology
- Location Arlington, TX
- Active Since 08/11/2005
- Last Updated 04/22/2013
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1790787612
Products in Payments
- TOLVAPTAN (Drug) $26,870
- Auryxia (Drug) $3,132
- LOKELMA (Drug) $949.81
- Kerendia (Drug) $764.75
- ACTHAR (Biological) $623.92
- Veltassa (Drug) $490.36
- RAYALDEE (Drug) $437.24
- Vascepa (Drug) $377.41
- JYNARQUE (Drug) $286.07
- TARPEYO (Drug) $268.91
- LUPKYNIS (Drug) $164.32
- BENLYSTA (Biological) $141.25
- FARXIGA (Drug) $129.67
- JARDIANCE (Drug) $126.79
- Renal - Sharesource (Device) $124.45
- AURYXIA (Drug) $115.90
- ENTRESTO (Drug) $108.82
- OXLUMO (Drug) $107.38
- Parsabiv (Biological) $97.26
- Velphoro (Drug) $93.07
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Arlington
Dr. Israel Hartman, M.d, M.D
Specialist — Payments: $944,018
Specialist $944,018
Dr. Gerard Engh, M.d, M.D
Specialist — Payments: $215,702
Specialist $215,702
Dr. Corey Wallach, Md, MD
Specialist — Payments: $115,045
Specialist $115,045
Dr. Robert Christie, M.d, M.D
Specialist — Payments: $17,207
Specialist $17,207
Dr. Patricia Rodriguez, M.d, M.D
Specialist — Payments: $11,339
Specialist $11,339
Rusty Milhoan, Md, MD
Specialist — Payments: $9,272
Specialist $9,272